
Zhejiang Taimei Medical Technology Co., Ltd.
2576.HKHKSETechnologySoftware - Application
最新数据
HK$5.50
−HK$0.045 · -0.81%
2576.HK公司概览
盘中时间采用HKT。市场数据可能有所延迟。
公司概况
公司网站Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
- 行业
- Software - Application
- 部门
- Technology
- 总部
- CN
- 首席执行官
- Wan Yunyun
- 上市以来
- 2024年10月8日
- 雇员
- 681
市场位置
52周区间
当前HK$5.50,
- 开盘价
- HK$5.50
- 前收盘价
- HK$5.545
- 成交量
- 55.58万
- 0.68× 平均值
- 平均成交量
- 81.24万
- 日均成交量
- 市值
- 31.01亿 HKD
- 贝塔
- 0.01
- 市场参考 1
- 50天平均值
- HK$5.8397
- 低于平均水平-5.82%
- 200天平均值
- HK$4.7971
- 高于平均水平+14.65%
财务数据
财务快照
最近十二个月财务健康
- 奥特曼 Z 分数
- 3.87
- 皮奥特罗斯基 F 分数
- 3 共 9 个
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(CNY) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.99亿 CNY | 5.51亿 CNY | 5.73亿 CNY | 5.49亿 CNY | 4.66亿 CNY |
| 销货成本 | 2.87亿 CNY | 3.26亿 CNY | 3.94亿 CNY | 3.64亿 CNY | 3.02亿 CNY |
| 毛利 | 2.12亿 CNY | 2.25亿 CNY | 1.79亿 CNY | 1.85亿 CNY | 1.64亿 CNY |
| 研究与开发 | 7663.39万 CNY | 8705.4万 CNY | 1.69亿 CNY | 2.34亿 CNY | 2.25亿 CNY |
| 销售、一般及管理费用 | 1.97亿 CNY | 3.82亿 CNY | 3.85亿 CNY | 4898.8万 CNY | 4621.9万 CNY |
| 营业费用 | 2.73亿 CNY | 4.77亿 CNY | 5.76亿 CNY | 6.28亿 CNY | 6.7亿 CNY |
| 利息收入 | 3472.25万 CNY | 3577.4万 CNY | 4165.4万 CNY | 2288.4万 CNY | 2873.8万 CNY |
| 利息支出 | 81.14万 CNY | 72.7万 CNY | 143.1万 CNY | 268.1万 CNY | 270.9万 CNY |
| 折旧和摊销 | 1946.48万 CNY | 3994.6万 CNY | 5196.2万 CNY | 5552.5万 CNY | 3650.6万 CNY |
| 营业利润 | −6150万 CNY | −2.52亿 CNY | −3.97亿 CNY | −4.43亿 CNY | −5.06亿 CNY |
| 净利润 | −4173.71万 CNY | −2.15亿 CNY | −3.47亿 CNY | −4.13亿 CNY | −4.8亿 CNY |
公司数据更新于 2026年8月24日。
财报历史与展望
- 最新财年每股收益
- -0.074
- 2025财年
- 最新财年收入
- 4.99亿 CNY
- 2025财年 · 同比-9.41%
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
2576.HK同业公司
继续GoAI的研究
在 GoAI 中研究2576.HKresearch.disclaimer





